308 related articles for article (PubMed ID: 12928387)
1. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases.
Caldwell SA; Ryan MH; McDuffie E; Abrams SI
J Immunol; 2003 Sep; 171(5):2402-12. PubMed ID: 12928387
[TBL] [Abstract][Full Text] [Related]
2. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
Winter H; Hu HM; Urba WJ; Fox BA
J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388
[TBL] [Abstract][Full Text] [Related]
3. Regression of extensive pulmonary metastases in mice by adoptive transfer of antigen-specific CD8(+) CTL reactive against tumor cells expressing a naturally occurring rejection epitope.
Ryan MH; Bristol JA; McDuffie E; Abrams SI
J Immunol; 2001 Oct; 167(8):4286-92. PubMed ID: 11591751
[TBL] [Abstract][Full Text] [Related]
4. T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-gamma mechanisms that cannot be predicted from in vitro T cell characteristics.
Peng L; Krauss JC; Plautz GE; Mukai S; Shu S; Cohen PA
J Immunol; 2000 Dec; 165(12):7116-24. PubMed ID: 11120842
[TBL] [Abstract][Full Text] [Related]
5. Virally infected hepatocytes are resistant to perforin-dependent CTL effector mechanisms.
Kafrouni MI; Brown GR; Thiele DL
J Immunol; 2001 Aug; 167(3):1566-74. PubMed ID: 11466378
[TBL] [Abstract][Full Text] [Related]
6. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
[TBL] [Abstract][Full Text] [Related]
7. Differential role of Fas/Fas ligand interactions in cytolysis of primary and metastatic colon carcinoma cell lines by human antigen-specific CD8+ CTL.
Bergmann-Leitner ES; Abrams SI
J Immunol; 2000 May; 164(9):4941-54. PubMed ID: 10779805
[TBL] [Abstract][Full Text] [Related]
8. Bcl-2 protects against Fas-based but not perforin-based T cell-mediated cytolysis.
Lee RK; Spielman J; Podack ER
Int Immunol; 1996 Jul; 8(7):991-1000. PubMed ID: 8757944
[TBL] [Abstract][Full Text] [Related]
9. IL-4 diminishes perforin-mediated and increases Fas ligand-mediated cytotoxicity In vivo.
Aung S; Graham BS
J Immunol; 2000 Apr; 164(7):3487-93. PubMed ID: 10725701
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
Winter H; Hu HM; McClain K; Urba WJ; Fox BA
J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
[TBL] [Abstract][Full Text] [Related]
11. Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-dependent diabetes mellitus.
Kreuwel HT; Morgan DJ; Krahl T; Ko A; Sarvetnick N; Sherman LA
J Immunol; 1999 Oct; 163(8):4335-41. PubMed ID: 10510373
[TBL] [Abstract][Full Text] [Related]
12. Disparate cytotoxic activity of nickel-specific CD8+ and CD4+ T cell subsets against keratinocytes.
Traidl C; Sebastiani S; Albanesi C; Merk HF; Puddu P; Girolomoni G; Cavani A
J Immunol; 2000 Sep; 165(6):3058-64. PubMed ID: 10975816
[TBL] [Abstract][Full Text] [Related]
13. Two types of anti-TL (thymus leukemia) CTL clones with distinct target specificities: differences in cytotoxic mechanisms and accessory molecule requirements.
Tsujimura K; Takahashi T; Iwase S; Matsudaira Y; Kaneko Y; Yagita H; Obata Y
J Immunol; 1998 Jun; 160(11):5253-61. PubMed ID: 9605121
[TBL] [Abstract][Full Text] [Related]
14. Identification of a population of CD4+ CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism.
Williams NS; Engelhard VH
J Immunol; 1996 Jan; 156(1):153-9. PubMed ID: 8598456
[TBL] [Abstract][Full Text] [Related]
15. Perforin-independent CD8(+) T-cell-mediated cytotoxicity of alveolar epithelial cells is preferentially mediated by tumor necrosis factor-alpha: relative insensitivity to Fas ligand.
Liu AN; Mohammed AZ; Rice WR; Fiedeldey DT; Liebermann JS; Whitsett JA; Braciale TJ; Enelow RI
Am J Respir Cell Mol Biol; 1999 May; 20(5):849-58. PubMed ID: 10226053
[TBL] [Abstract][Full Text] [Related]
16. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity.
Kataoka T; Shinohara N; Takayama H; Takaku K; Kondo S; Yonehara S; Nagai K
J Immunol; 1996 May; 156(10):3678-86. PubMed ID: 8621902
[TBL] [Abstract][Full Text] [Related]
17. Differential contribution of Fas- and perforin-mediated mechanisms to the cell-mediated cytotoxic activity of naive and in vivo-primed intestinal intraepithelial lymphocytes.
Corazza N; Müller S; Brunner T; Kägi D; Mueller C
J Immunol; 2000 Jan; 164(1):398-403. PubMed ID: 10605035
[TBL] [Abstract][Full Text] [Related]
18. Fas ligand (CD95L) protects neurons against perforin-mediated T lymphocyte cytotoxicity.
Medana I; Li Z; Flügel A; Tschopp J; Wekerle H; Neumann H
J Immunol; 2001 Jul; 167(2):674-81. PubMed ID: 11441070
[TBL] [Abstract][Full Text] [Related]
19. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
[TBL] [Abstract][Full Text] [Related]
20. Fas ligand-mediated bystander lysis of syngeneic cells in response to an allogeneic stimulus.
Smyth MJ
J Immunol; 1997 Jun; 158(12):5765-72. PubMed ID: 9190927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
